SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending as investors and social media users weigh significant volatility alongside intense political debate regarding its connection to the former president's policy agenda. The community remains deeply polarized, with active discussions focusing on the company's financial performance, the impact of its association with Trump, and the broader implications for the stock's stability.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is experiencing heightened investor attention following a significant stake disclosure by the Situational Awareness fund and strong earnings, fueling speculation about its role in the AI data center energy supply chain. The community is actively discussing potential short squeeze risks due to elevated short interest, the strategic importance of its domestic solar manufacturing, and the upcoming G2 facility expansion in Austin.

Enhanced Group, Inc. is an elite sports competition and performance products company committed to providing athletes and consumers with products that support health, performance, and recovery. The company offers a portfolio of products and experiences that combine athletic competition, scientific innovation, and consumer engagement. The company is headquartered in New York, NY.

Enhanced Group Inc. - Ordinary Shares - Class A

Enhanced Group Inc

Enhanced Group Inc. is trending as it completes its transition to the NYSE and builds momentum toward its inaugural Enhanced Games, a competition focused on performance optimization. Community sentiment is currently driven by a stream of strategic partnerships, including a significant distribution deal with Roku and a creator-focused agreement with Zoop, as investors weigh the potential of this disruptive sports and telehealth platform.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that exceeded top-line and bottom-line expectations, fueling significant after-hours price action. Investors are actively debating the sustainability of the company's subscription growth and long-term valuation, while tracking how its hospitality-focused software solutions maintain momentum amid shifting industry spending.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is currently a major topic of conversation as the company prepares to present late-breaking data on its WVE-006 candidate at the upcoming American Thoracic Society conference. Investors and the community are closely monitoring this readout and related pipeline milestones, viewing the company as a high-potential acquisition target within the competitive obesity and genetic medicine sectors.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XP Inc. is currently a point of contention among traders, with ongoing debates centering on the stock's significant long-term downtrend versus its potential for a recovery driven by its Brazilian financial services footprint. While some community members remain skeptical, pointing to historical volatility and short-seller interest, others are highlighting institutional buying activity and the company's recent capital distribution programs as signals of a possible turnaround.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The bond market is experiencing intense selling pressure as investors struggle with elevated energy costs and mounting concerns over fiscal debt, leading to a critical test of support levels for TLT. The community is actively debating whether current price action signals a deeper structural shift or an oversold opportunity, while closely monitoring central bank responses and the ongoing geopolitical instability as the primary drivers of volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending following an aggressive display of data at the AUA conference where the company announced an exclusive U.S. supply agreement for the Tokyo-172 BCG strain to help alleviate the national supply shortage. Community sentiment is highly energized by this news and recent patent updates, with investors actively discussing the company's potential to disrupt the bladder cancer standard of care despite ongoing volatility and intense scrutiny surrounding FDA regulatory pathways.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

TOYO is seeing strong investor interest driven by a significant 150 million dollar contract and the launch of commercial operations at its new Texas facility, which positions the company to benefit from domestic incentives. Community members are highly bullish, frequently pointing to the company's strong revenue growth, profitability, and low valuation compared to solar sector peers as key reasons for their long-term confidence.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is currently trending as investors weigh strong demand for its autonomous drone and laser defense systems against volatility from recent leadership changes and defense sector headwinds. The community is actively debating the company's long-term growth potential and contract visibility amid shifting geopolitical budget priorities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion Status Update: Experts Discuss Icovamenib's Promise Ahead of ADA 2026

Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre...

Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of Biomea Fusion in a research note on Tuesday. They issued a 'market outperform' rating and a $9.00 target price on the stock...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings...

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company's COVALENT-112 proof-of-concept...

Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research report on Tuesday...

Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-biomea-fusion-inc-stock...

Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research note on Wednesday...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment...

Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts

Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator...

Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes

Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes.

BMF-6...

This account has been verified as an official BMEA representative.

Verified Account

Biomea Fusion IR

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest BMEA News

BMEABiomea Fusion Inc